ATE489969T1 - Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung - Google Patents
Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendungInfo
- Publication number
- ATE489969T1 ATE489969T1 AT03760672T AT03760672T ATE489969T1 AT E489969 T1 ATE489969 T1 AT E489969T1 AT 03760672 T AT03760672 T AT 03760672T AT 03760672 T AT03760672 T AT 03760672T AT E489969 T1 ATE489969 T1 AT E489969T1
- Authority
- AT
- Austria
- Prior art keywords
- vlps
- antigens
- cpg
- packaged
- adjuvants
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 239000013566 allergen Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38989802P | 2002-06-20 | 2002-06-20 | |
| PCT/EP2003/006541 WO2004000351A1 (en) | 2002-06-20 | 2003-06-20 | Packaged virus-like particles for use as adjuvants: method of preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE489969T1 true ATE489969T1 (de) | 2010-12-15 |
Family
ID=30000481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03760672T ATE489969T1 (de) | 2002-06-20 | 2003-06-20 | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040005338A1 (de) |
| EP (1) | EP1513552B1 (de) |
| JP (1) | JP4598519B2 (de) |
| CN (1) | CN1662253A (de) |
| AT (1) | ATE489969T1 (de) |
| AU (1) | AU2003242742B2 (de) |
| BR (1) | BR0311995A (de) |
| CA (1) | CA2488856A1 (de) |
| DE (1) | DE60335186D1 (de) |
| IL (1) | IL164812A0 (de) |
| MX (1) | MXPA04011210A (de) |
| NZ (1) | NZ537002A (de) |
| PL (1) | PL375306A1 (de) |
| RU (1) | RU2322257C2 (de) |
| WO (1) | WO2004000351A1 (de) |
| ZA (1) | ZA200408709B (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094409B2 (en) * | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| CA2492826C (en) | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| DE602004029868D1 (de) * | 2003-03-05 | 2010-12-16 | Chemo Sero Therapeut Res Inst | Verfahren zur herstellung eines heterologen proteins in e. coli |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| ZA200507562B (en) * | 2003-03-26 | 2006-11-29 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
| ES2217967B1 (es) * | 2003-03-31 | 2006-01-01 | Consejo Sup. Investig. Cientificas | Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv. |
| KR20060031607A (ko) * | 2003-07-10 | 2006-04-12 | 사이토스 바이오테크놀로지 아게 | 패킹된 바이러스-양 입자 |
| US20060182793A1 (en) * | 2003-07-22 | 2006-08-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
| ES2307346B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
| ES2307345B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
| JP3976742B2 (ja) | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド |
| US7964196B2 (en) * | 2004-05-25 | 2011-06-21 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| JP2008513035A (ja) * | 2004-09-21 | 2008-05-01 | サイトス バイオテクノロジー アーゲー | Ａｐ２０５のコートタンパク質と抗原性ポリペプチドとの融合タンパク質を含んでなるウイルス粒子 |
| WO2006037787A2 (en) * | 2004-10-05 | 2006-04-13 | Cytos Biotechnology Ag | Vlp-antigen conjugates and their uses as vaccines |
| ES2310062B1 (es) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| NZ569741A (en) * | 2005-12-14 | 2012-02-24 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| CN100418583C (zh) * | 2006-02-21 | 2008-09-17 | 朱鸿飞 | 预防和治疗乳腺炎的药物组合物 |
| EP2018156B1 (de) * | 2006-04-07 | 2010-03-17 | Chimeros, Inc. | Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen |
| JP5437797B2 (ja) | 2006-06-12 | 2014-03-12 | サイトス バイオテクノロジー アーゲー | Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法 |
| AU2013204383B2 (en) * | 2006-06-12 | 2016-09-22 | Kuros Us Llc | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
| AU2007345768B2 (en) * | 2006-07-27 | 2013-08-01 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| EP2044224A4 (de) * | 2006-07-27 | 2011-04-13 | Ligocyte Pharmaceuticals Inc | Chimärische virusähnliche partikel |
| SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| CA2671873C (en) | 2006-12-12 | 2018-10-09 | Brian Stephen Sproat | Oligonucleotides containing high concentrations of guanine monomers |
| US20090226525A1 (en) * | 2007-04-09 | 2009-09-10 | Chimeros Inc. | Self-assembling nanoparticle drug delivery system |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| CN101918028B (zh) | 2007-09-18 | 2015-01-07 | 莱戈赛特医药股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
| US8986597B2 (en) * | 2007-10-31 | 2015-03-24 | Corning Incorporated | Low creep refractory ceramic and method of making |
| US20110014231A1 (en) * | 2007-11-05 | 2011-01-20 | Mor Research Applications Ltd | Anti-measles cancer immunotherapy |
| NO339169B1 (no) * | 2008-04-24 | 2016-11-14 | Chemoforma Ltd | Funksjonelt fiskefôr omfattende peptidoglykan og nukleotider |
| DK2324113T3 (en) * | 2008-08-08 | 2018-04-16 | Takeda Vaccines Inc | VIRUS-LIKE PARTICLES INCLUDING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR INCREASED CRYSTAL REACTIVITY |
| KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
| ES2683352T3 (es) | 2009-04-13 | 2018-09-26 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Partículas de HPV y usos de las mismas |
| WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| WO2011056899A2 (en) | 2009-11-03 | 2011-05-12 | Ligocyte Pharmaceuticals, Inc. | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
| RU2440141C1 (ru) * | 2010-05-31 | 2012-01-20 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) | Способ регуляции иммуногенности антигена |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| WO2012070974A1 (ru) * | 2010-11-22 | 2012-05-31 | Farber Boris Slavinovich | Вакцины с повышенной иммуногенностью и способы их получения |
| KR101376675B1 (ko) * | 2011-04-19 | 2014-03-20 | 광주과학기술원 | 이미징 및 운반 이중기능 나노입자－기반 백신 전달체 |
| US8795678B2 (en) * | 2011-05-13 | 2014-08-05 | Academia Sinica | TLR-2 agonists and methods of use thereof |
| MX356586B (es) | 2011-07-11 | 2018-06-05 | Takeda Vaccines Inc | Formulaciones parenterales de vacunas contra los norovirus. |
| BR112014001244A2 (pt) | 2011-07-19 | 2017-02-21 | Wave Life Sciences Pte Ltd | métodos para a síntese de ácidos nucléicos funcionalizados |
| EP2747774A4 (de) | 2011-09-09 | 2015-02-11 | Biomed Realty L P | Verfahren und zusammensetzungen zur kontrolle einer virusproteinassemblierung |
| CN102512671A (zh) * | 2011-12-16 | 2012-06-27 | 厦门大学 | 抗o型口蹄疫的类病毒颗粒疫苗及其制备方法 |
| US9700639B2 (en) | 2012-02-07 | 2017-07-11 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| CN103421117B (zh) * | 2012-05-16 | 2016-08-03 | 李岱宗 | 一种免疫增强型病毒样颗粒、其表达载体及其制备与应用 |
| BR112015000723A2 (pt) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
| CN112007045A (zh) | 2012-07-13 | 2020-12-01 | 波涛生命科学有限公司 | 手性控制 |
| ES2862073T3 (es) | 2012-07-13 | 2021-10-06 | Wave Life Sciences Ltd | Grupo auxiliar asimétrico |
| WO2015024992A2 (en) * | 2013-08-22 | 2015-02-26 | Cytos Biotechnology Ag | Treatment of asthma |
| EP3517130B1 (de) | 2013-09-18 | 2022-03-30 | Aura Biosciences, Inc. | Methode zur herstellung photosensitiver moleküle |
| EP3095459A4 (de) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel |
| EP3095460A4 (de) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| US20150355147A1 (en) * | 2014-06-06 | 2015-12-10 | Biogénesis Bagó Uruguay S.A. | High throughput quantification and characterization of foot and mouth disease virus and products thereof |
| RU2017114964A (ru) | 2014-10-02 | 2018-11-07 | Протива Байотерапьютикс, Инк. | Композиции и способы для подавления экспрессии гена вируса гепатита в |
| US10251970B1 (en) | 2014-12-30 | 2019-04-09 | Zee Company | Air sanitation apparatus for food processing tanks having air agitation piping and methods thereof |
| JP2018532801A (ja) | 2015-10-30 | 2018-11-08 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 標的化がん療法 |
| CN108779473A (zh) * | 2016-03-16 | 2018-11-09 | 法国居里学院 | 用于制备具有环二核苷酸的病毒颗粒的方法和所述颗粒用于治疗癌症的用途 |
| EP3295956A1 (de) | 2016-09-20 | 2018-03-21 | Biomay Ag | Polypeptidkonstrukt mit fragmenten von allergenen |
| TWI634899B (zh) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物 |
| EP3752194A4 (de) | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | Zusammensetzungen und verfahren für die tumorimmuntherapie |
| IL277680B2 (en) | 2018-04-09 | 2025-08-01 | Checkmate Pharmaceuticals Inc | Packaging oligonucleotides into virus-like particles |
| CN112639077B (zh) * | 2018-08-07 | 2023-06-20 | 中国科学院生物物理研究所 | 活化cd4+ t细胞的方法 |
| CN110257922A (zh) * | 2019-07-19 | 2019-09-20 | 苏州盛天力离心机制造有限公司 | 羽毛洗涤脱水一体机 |
| WO2021022008A1 (en) * | 2019-07-30 | 2021-02-04 | Verndari, Inc. | Virus-like particle vaccines |
| JP7072604B2 (ja) * | 2020-06-23 | 2022-05-20 | アンスティテュ・クリー | 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用 |
| WO2022051401A1 (en) * | 2020-09-02 | 2022-03-10 | The Regents Of The University Of California | Covid assay controls |
| CN114632148B (zh) * | 2020-12-15 | 2024-08-09 | 榕森生物科技(北京)有限公司 | 病原样抗原疫苗及其制备方法 |
| CN115927400A (zh) * | 2022-08-11 | 2023-04-07 | 中国动物卫生与流行病学中心 | 一种含口蹄疫病毒rna片段的假病毒颗粒及其制备方法和应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US5374426A (en) * | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| US4918166A (en) * | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE139258T1 (de) * | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5334394A (en) * | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
| SE9003978D0 (sv) * | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| GB9114003D0 (en) * | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
| FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| US6004763A (en) * | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
| DE69418699T2 (de) * | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| WO1994017813A1 (en) * | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| DK0732936T3 (da) * | 1993-12-09 | 2000-09-04 | Heinrich Exner | Adjuvans til antigener, fremgangsmåde til fremstilling og anvendelse |
| US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| DK0772619T4 (da) * | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5935821A (en) * | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US5770380A (en) * | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| WO1998050071A1 (en) * | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
| DE69838294T2 (de) * | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| WO1998058951A1 (en) * | 1997-06-23 | 1998-12-30 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to hla molecules, and the use thereof |
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| CA2320488C (en) * | 1998-02-12 | 2007-03-06 | Immune Complex, Corporation | Strategically modified hepatitis b core proteins and their derivatives |
| JP2002514397A (ja) * | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧオリゴヌクレオチドを用いる造血調節の方法 |
| PT1104306E (pt) * | 1998-08-10 | 2006-05-31 | Antigenics Inc | Composicoes de cpg e adjuvantes de saponina e seus metodos |
| US5962636A (en) * | 1998-08-12 | 1999-10-05 | Amgen Canada Inc. | Peptides capable of modulating inflammatory heart disease |
| DE69939836D1 (de) * | 1998-11-30 | 2008-12-11 | Cytos Biotechnology Ag | Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung |
| US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| PL354997A1 (en) * | 1999-09-25 | 2004-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| WO2001051083A2 (en) * | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| EP1311288A1 (de) * | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunstimulierende nukleinsäuren zur induktion einer th-2 immunreaktion |
| AT409085B (de) * | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| CA2421683C (en) * | 2000-09-28 | 2009-09-15 | Chiron Corporation | Microparticles for delivery of the heterologous nucleic acids |
| IL155282A0 (en) * | 2000-10-18 | 2003-11-23 | Glaxosmithkline Biolog Sa | Vaccines |
| US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| CA2492826C (en) * | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| EP1532167B1 (de) * | 2002-07-17 | 2012-01-25 | Cytos Biotechnology AG | Molekulare antigen-anordnung durch verwendung eines virus-ähnlichen partikels vom virus ap205 |
| KR101228376B1 (ko) * | 2002-07-18 | 2013-01-31 | 사이토스 바이오테크놀로지 아게 | 합텐-캐리어 컨쥬게이트 및 그의 용도 |
| NZ537001A (en) * | 2002-07-19 | 2007-04-27 | Cytos Biotechnology Ag | A composition comprising a virus-like particle and at least ghrelin or a ghrelin-derived peptide bound thereto |
| ZA200507562B (en) * | 2003-03-26 | 2006-11-29 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
-
2003
- 2003-06-20 AU AU2003242742A patent/AU2003242742B2/en not_active Ceased
- 2003-06-20 PL PL03375306A patent/PL375306A1/xx not_active Application Discontinuation
- 2003-06-20 WO PCT/EP2003/006541 patent/WO2004000351A1/en not_active Ceased
- 2003-06-20 DE DE60335186T patent/DE60335186D1/de not_active Expired - Lifetime
- 2003-06-20 BR BR0311995-5A patent/BR0311995A/pt not_active IP Right Cessation
- 2003-06-20 CA CA002488856A patent/CA2488856A1/en not_active Abandoned
- 2003-06-20 NZ NZ537002A patent/NZ537002A/en not_active IP Right Cessation
- 2003-06-20 US US10/465,811 patent/US20040005338A1/en not_active Abandoned
- 2003-06-20 RU RU2005101206/13A patent/RU2322257C2/ru not_active IP Right Cessation
- 2003-06-20 CN CN038142228A patent/CN1662253A/zh active Pending
- 2003-06-20 EP EP03760672A patent/EP1513552B1/de not_active Expired - Lifetime
- 2003-06-20 MX MXPA04011210A patent/MXPA04011210A/es active IP Right Grant
- 2003-06-20 JP JP2004514823A patent/JP4598519B2/ja not_active Expired - Fee Related
- 2003-06-20 AT AT03760672T patent/ATE489969T1/de not_active IP Right Cessation
-
2004
- 2004-06-20 IL IL16481204A patent/IL164812A0/xx unknown
- 2004-10-27 ZA ZA200408709A patent/ZA200408709B/en unknown
-
2010
- 2010-05-28 US US12/790,708 patent/US20110070267A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ537002A (en) | 2006-06-30 |
| ZA200408709B (en) | 2005-11-18 |
| IL164812A0 (en) | 2005-12-18 |
| US20110070267A1 (en) | 2011-03-24 |
| WO2004000351A1 (en) | 2003-12-31 |
| JP4598519B2 (ja) | 2010-12-15 |
| MXPA04011210A (es) | 2005-02-14 |
| DE60335186D1 (de) | 2011-01-13 |
| RU2322257C2 (ru) | 2008-04-20 |
| CN1662253A (zh) | 2005-08-31 |
| WO2004000351A8 (en) | 2005-02-03 |
| AU2003242742A1 (en) | 2004-01-06 |
| JP2006502979A (ja) | 2006-01-26 |
| BR0311995A (pt) | 2005-04-05 |
| EP1513552A1 (de) | 2005-03-16 |
| HK1074578A1 (en) | 2005-11-18 |
| AU2003242742B2 (en) | 2009-04-30 |
| RU2005101206A (ru) | 2005-06-27 |
| US20040005338A1 (en) | 2004-01-08 |
| CA2488856A1 (en) | 2003-12-31 |
| EP1513552B1 (de) | 2010-12-01 |
| PL375306A1 (en) | 2005-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE489969T1 (de) | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung | |
| DE60234375D1 (de) | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG | |
| WO2004084939A3 (en) | Hiv-peptide-carrier-conjugates | |
| ATE494910T1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
| Skrastina et al. | Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles | |
| WO2004084936A8 (en) | Modified free-living microbes, vaccine compositions and methods of use thereof | |
| WO2005009463A3 (en) | Antigen-presenting cell vaccines and methods of use thereof | |
| NO20062674L (no) | Optimalisert uttrykking av HPV58-L1 i gjaer | |
| IL150602A0 (en) | Proteosome influenza vaccine | |
| WO2002034205A3 (en) | Using heat shock proteins to increase immune response | |
| WO2002056905A3 (en) | Molecular antigen array | |
| BR0316758A (pt) | Vacinas baseadas em levedura como imunoterapia | |
| WO2006097530A3 (en) | Cat allergen fusion proteins and uses thereof | |
| SG156652A1 (en) | Yeast-based therapeutic for chronic hepatitis c infection | |
| EP1200109A4 (de) | Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c | |
| WO2005007673A3 (en) | Immunogenic peptides | |
| JP2011519869A5 (de) | ||
| ATE412428T1 (de) | Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen | |
| WO2005117983A3 (en) | Carrier conjugates of tnf-peptides | |
| WO2006027300A3 (en) | Carrier conjugates of gnrh-peptides | |
| WO2008082719A3 (en) | Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors | |
| AR041515A1 (es) | Vacuna a dna contra el virus de papiloma humano | |
| Gandhapudi et al. | Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice., 2023, 15, 432 | |
| WO2003025002A3 (en) | Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection | |
| Monteyne et al. | Addressing Unmet Medical Needs Through Tailored Vaccine Design: The Importance of Adjuvant Systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |